Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2399-2408

  Markman, B ^a   Tabernero, J ^a   Krop, I ^b   Shapiro, G I ^b   Siu, L ^c   Chen, L C ^d   Mita, M ^e   Melendez cuero, M ^f   Stutvoet, S ^f   Birle, D ^g   Anak, O ^f   Hackl, W ^f   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d NEVADA CANCER INSTITUTE   (United States)

^e University of Texas Health Science Center at San Antonio   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Anticancer agent; BGT226; Dual inhibitor; MTOR catalytic inhibitor; PI3K pathway; Solid tumors

Indexed keywords

APREPITANT; ATROPINE PLUS DIPHENOXYLATE; BGT 226; FLUORODEOXYGLUCOSE F 18; LOPERAMIDE; LORAZEPAM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METOCLOPRAMIDE; PALONOSETRON; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROCHLORPERAZINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER INHIBITION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; HYPERURICEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC REGULATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR BIOPSY;

EID: 84865562515     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds011     Document Type: Article

References (20)

1. Katso R, Okkenhaug K, Ahmadi K et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
3. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.
4. Liu P, Cheng H, Roberts TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
5. Vogt PK, Kang S, Elsliger MA et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 2007; 32: 342-349.
6. Brognard J, Clark AS, Ni Y et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
7. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
8. Hu L, Hofmann J, Lu Y et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092.
9. Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
10. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
11. Maira SM, Voliva C, Garcia-Echeverria C. Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 2008; 12: 223-238.
12. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
13. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420-2439.
14. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998; 17: 1103-1120.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
17. Burris H, Rodon J, Sharma S et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients with advanced solid tumors. Presented at the 2010 American Society of Clinical Oncology Annual Meeting (Abstr 3005). Chicago, IL June 4-8, 2010.
18. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-290.
19. Ihle NT, Lemos R, Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009; 69: 143-150.
20. Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.